Alpha DNA Investment Management’s Procore PCOR Stock Holding History

Alpha DNA Investment Management’s Portfolio PCOR Stock Details PCOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-7,880	Closed	-$648K	–	232
2024 Q1	$648K	Buy	+7,880	New	+$585K	0.24%	89
2023 Q4	–	Sell	-8,652	Closed	-$565K	–	224
2023 Q3	$565K	Sell	8,652 -4,282	-33%	-$286K	0.23%	105
2023 Q2	$842K	Buy	+12,934	New	+$761K	0.28%	79
2023 Q1	–	Sell	-23,428	Closed	-$1.11M	–	191
2022 Q4	$1.11M	Buy	+23,428	New	+$1.2M	0.39%	73

Other funds holding PCOR

Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

XN LP New York $2.72B AUM 46.67% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Tiger Global Management New York $22.8B AUM 30.07% 1-Year Est. Return

Alpha DNA Investment Management's PCOR Position: Q2 2024 in Review

Alpha DNA Investment Management sold out of Procore (PCOR) in Q2 2024, closing a stake of 7,880 shares — an estimated $648K sold.

Alpha DNA Investment Management first reported a position in PCOR in Q4 2022 and held it in 4 quarters. The position peaked at $1.11M in Q4 2022. 393 funds tracked by Wall St. Rank hold PCOR as of Q2 2024.

Alpha DNA Investment Management reported no remaining Procore position as of Q2 2024 after selling out during the quarter.
Alpha DNA Investment Management sold 7,880 Procore shares in Q2 2024, an estimated $648K.
Alpha DNA Investment Management first reported a position in Procore in Q4 2022 and held it in 4 quarters.
Alpha DNA Investment Management's Procore position peaked at $1.11M in Q4 2022.
393 funds tracked by Wall St. Rank held Procore as of Q2 2024.

Based on Alpha DNA Investment Management's 13F filing for Q2 2024, filed 14 Aug 2024.